• TBST Workflows for Cleaner Antibody Assays

  2026-09-23

  Learn how TBST supports antibody blocking, dilution, and washing across Western blot, IF, and IHC workflows—and where detergent compatibility needs validation. A breast cancer metastasis study provides a useful example of how cleaner downstream protein readouts can complement, but not replace, direct binding and functional assays.

• Gemcitabine HCl in Pancreatic Cancer Research

  2026-09-23

  Gemcitabine HCl is a deoxycytidine analog that produces DNA replication inhibition and apoptosis induction in cancer cells. Its combination with cell assays and longitudinal MRI supports mechanism-focused studies of tumor growth suppression in pancreatic cancer models.

• Tau Ser356, NUAK Inhibition, and Alzheimer’s Pathology

  2026-09-22

  Taylor et al. characterize tau phosphorylated at serine 356 as a pathology-associated species that increases with Alzheimer’s disease progression and localizes near synapses. Their ex vivo experiments show that NUAK inhibition with WZ4003 lowers p-tau Ser356 in human brain slices, while mouse slice cultures display broader and potentially confounding losses of tau and synaptic proteins.

• Anagliptin: From DPP-4 to Vascular Biology

  2026-09-22

  Anagliptin (SK-0403) is best understood not only as a potent DPP-4 inhibitor, but also as a mechanistic probe for vascular smooth-muscle biology. This article interprets the rabbit-aorta evidence, explains the Kv channel and SERCA pump findings, and translates them into more discriminating assay decisions.

• How α-Synuclein Condensates Sort Molecules by Charge

  2026-09-21

  The reference study shows that α-synuclein condensates formed by liquid–liquid phase separation possess a strongly negative electrostatic potential that selectively controls molecular partitioning. By combining charge-varied fluorescent probes, zeta-potential measurements, and a differentiated neuronal cell model, the authors connect condensate electrostatics with both phase behavior and intracellular molecular organization.

• Dextrose (D-glucose) for Tumor Metabolism Assays

  2026-09-21

  Use Dextrose (D-glucose) to build controlled glucose and oxygen conditions for tumor–immune co-culture, glycolysis, and cellular energy production studies. This workflow emphasizes dose arithmetic, hypoxia-aware controls, and troubleshooting steps that distinguish nutrient effects from handling artifacts.

• HRP Goat Anti-Mouse IgG (H+L) Antibody

  2026-09-20

  K1221 provides HRP-based detection of mouse IgG primary antibodies in Western blotting, ELISA, IHC, and ICC workflows. It should be selected when the primary antibody is mouse-derived; it is not a substitute for a fluorophore-conjugated secondary, and its performance must be checked in samples containing endogenous mouse immunoglobulins.

• MK-4827 (Niraparib) in PARP Research

  2026-09-19

  MK-4827 (Niraparib) gives researchers a selective PARP-1/-2 inhibition tool for modeling DNA damage repair inhibition, BRCA-associated vulnerability, and treatment resistance. This workflow-focused guide shows how to build dose-response, cisplatin-sequencing, and chemo- and radio-potentiation experiments while avoiding common formulation and interpretation errors.

• Mycoplasma pneumoniae Resistance in Beijing, 2023

  2026-09-18

  This study provides a contemporaneous, multidimensional assessment of Mycoplasma pneumoniae resistance in children from Beijing, combining MIC data with strain genotyping and clinical observations. Its most important practical finding is that erythromycin and azithromycin were ineffective in vitro against the examined isolates, while acetylspiramycin showed comparatively lower MICs, underscoring the value of local surveillance and drug-specific testing.

• Stable Yeast Expression of Exendin-4 for Type 2 Diabetes

  2026-09-18

  A 2024 Frontiers in Systems Biology study established a proof-of-concept platform for producing Exendin-4 through chromosomally integrated Saccharomyces cerevisiae, alongside recombinant-expression designs in Escherichia coli. The findings support further access-oriented type 2 diabetes research, while leaving peptide yield, purification, receptor activity, formulation, and safety for future investigation.

• NUAK Inhibition and Tau Ser356 in Alzheimer’s

  2026-09-17

  Taylor et al. investigate tau phosphorylated at serine 356 as an Alzheimer’s disease-associated species and test whether NUAK inhibition can modify it in mouse and human brain tissue. The study combines post-mortem array tomography with mouse and live human organotypic brain-slice cultures, revealing a disease-linked p-tau Ser356 signal and species-dependent responses to WZ4003.

• ssBIR and DNA Damage Amplification in Mouse Oocytes

  2026-09-17

  The reference study identifies a short-scale form of break-induced replication (ssBIR) in fully grown mouse oocytes and connects it to DNA double-strand break amplification. Its combination of EdU labeling, damage-foci analysis, and pathway inhibitors provides a useful framework for separating repair-associated DNA synthesis from background replication, while also highlighting important limits of indirect readouts.

• Ceapin-A7: Mapping ATF6α in Translational ER Stress

  2026-09-16

  Ceapin-A7 is a selective ER stress blocker that enables branch-specific ATF6α pathway inhibition. This thought-leadership guide connects its use as a chemical probe with the PTX3–TLR4/NF-κB–FGF21 axis reported in glucocorticoid-induced osteonecrosis, while defining practical validation steps, translational boundaries, and opportunities for more rigorous endoplasmic reticulum stress research.

• Calpeptin: From Calpain Biology to Translation

  2026-09-16

  Calpeptin is a nanomolar calpain inhibitor that connects calcium-dependent protease biology with pulmonary fibrosis research, inflammatory mediator control, and extracellular vesicle studies. This translational guide shows how to build evidence-driven workflows without confusing promising preclinical signals with clinical validation.

• GS-4997 in Lupus Nephritis Tubulointerstitial Injury

  2026-09-15

  This study identifies ASK1 signaling as a pharmacologically tractable contributor to tubulointerstitial injury in lupus nephritis. In lupus-prone mice and LPS-stimulated HK-2 cells, GS-4997 reduced inflammation, fibrosis, tubular damage, and downstream p38/JNK activation, supporting further investigation of ASK1 inhibition in renal stress models.

8192 records 3/547 page Previous Next 12345 下5页 Last page